YouTube Facebook LinkedIn Google+ Twitter Xingrss  

News Blast


Feb 15, 2006

HIT-TO-LEAD
Acumen Pharmaceuticals and deCODE chemistry initiated a drug discovery program to identify potential therapeutic treatments for Alzheimer’s disease. The program initially involves a hit-to-lead campaign to  explore screening hits that Acumen identified in its small molecule anti-ADDL platform. As validated lead series develop, deCODE will conduct lead optimization focused on potency in Acumen’s assay and optimization of pharmaceutical properties.

WHOLE GENOME
Perlegen Sciences announced a four-year research collaboration with Pfizer for whole-genome and replication studies that may identify genes associated with major diseases and predict patient responses to certain medicines. Researchers from both companies will conduct whole-genome studies involving DNA samples from clinical trials.

GLEEVEC RESISTANCE
Ambit Biosciences announced the publication in Cancer Research of a crystal structure explaining why the Aurora kinase inhibitor VX-680 is active against Gleevec-resistant forms of the kinase BCR-ABL, including the T315I mutant variant, the most common drug-resistant mutation in chronic myelogenous leukemia.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact  Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.